CRA-Z 

2014 - Study ~ L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies.

2013 - Study ~ Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy.

2013 - Study ~ Striatal Molecular Signature of Subchronic Subthalamic Nucleus High Frequency
Stimulation in Parkinsonian Rat.

2013 - Study ~ A spontaneous deletion of α-Synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: Effects on alcohol consumption

2013 - Study ~ Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5- HT1A receptors activation in mice.

2013 - Study ~ Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review.

2013 - Study ~ Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine

2013 - Study ~ Δ9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE.

2013 - Study ~ Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson ́s disease.

2013 - Study ~ The Influence of Cannabinoids on Generic Traits of Neurodegeneration.

2013 - Study ~ The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia

2012 - Study ~ The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.

2012 - Study ~ Δ(9) -THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

2012 - Study ~ The decrease of dopamine D(2)/D(3) receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB(1) cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D(2)/D(3) antagonist [(3)H]raclopride and the novel CB(1) inverse agonist [(125)I]SD7015.

2012 - Study ~ Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

2012 - Study ~ Contribution of genetic variants to pain susceptibility in Parkinson disease

2011 - Study ~ Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction.

2011 - Study ~ Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinson's Disease

2011 - Study ~ Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

2011 - Study ~ Homeostatic changes of the endocannabinoid system in Parkinson's disease.

2011 - Study ~ Prospects for cannabinoid therapies in basal ganglia disorders.

2011 - Study ~ Symptom-relieving and neuroprotective effects of the phytocannabinoid D(9) -THCV in animal models of Parkinson's disease

2011 - Study ~ Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation.

2010 - Study ~ Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

2010 - Study ~ Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders

2010 - Study ~ Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.

2009 - Study ~ WIN55,212-2, a Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss in the MPTP Mouse Model of Parkinson’s Disease

2009 - Study ~ Cannabidiol: a promising drug for neurodegenerative disorders?

2009 - Study ~ The endocannabinoid system as a target for the treatment of motor dysfunction.

2009 - Study ~ Cannabidiol for the treatment of psychosis in Parkinson’s disease

2008 - Study ~ The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease.

2007 - Study ~ The endocannabinoid system in targeting inflammatory neurodegenerative diseases

2007 - Study ~ Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

2007 - Study ~ Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.

2007 - Study ~ Cannabinoids and neuroprotection in motor-related disorders.

2007 - News ~ Marijuana Against Parkinson?

2007 - News ~ Marijuana-Like Chemicals Helps Treat Parkinson's

2007 - News ~ Parkinsons' Helped By Marijuana-Like Chemicals In Brain

2006 - Study ~ Cannabinoids In Medicine: A Review Of Their Therapeutic Potential

2005 - Study ~ Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)

2005 - Study ~ Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

2004 - News ~ Marijuana Compounds May Aid Parkinson's Disease

2003 - Study ~ Therapeutic potential of cannabinoids in CNS disease.

2002 - Study ~ Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

2000 - Study ~ Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease

1999 - Study ~ Cannabinoids in parkinsonism

1999 - Study ~ Cannabis in movement disorders.

1999 - News ~ Why your brain is primed for a high

1998 - Study ~ The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD).

1986 - Study ~ Open label evaluation of cannabidiol in dystonic movement disorders.

1985 - Study ~ Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.

1981 - Study ~ Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.

Top Home